Laboratory study of a scavenging mask system to evaluate and control airborne pathogens for healthcare workers in the Post Anesthesia Care Unit (PACU) and Intensive Care Unit (ICU)

This laboratory study evaluated the usefulness of a new market available scavenging system (patient mask and filter) in controlling the spread of airborne pathogens by: 1.Develop a laboratory simulation of an infectious patient exhaling a range of respirable bacteria and viruses into a laboratory hood. 2. Compare and contrast capabilities of the market-available scavenging system to reduce and control pathogens in a laboratory setting versus not using a scavenging system. 3. Evaluate the effectiveness of the scavenging system\u27s filter and alternative HEPA filters in capturing these pathogens. A life-like manikin head equipped with a bioaerosol collision nebulizer was set up to simulate a person exhausting pathogenic droplets. The study\u27s hypothesis was tested by using two different scenarios: 1. The scavenging system was used the entire duration of the trial (Case) 2. The scavenging system was not used at all during the trial (Control). The nebulizer used multiple types of respirable pathogens (bacteria and viruses) to represent different size pathogens to evaluate the scavenging system\u27s ability to capture a range of pathogens likely to be found in infectious patients. Pathogens that may escape the scavenging system were captured using liquid impingers, and pathogens inside the scavenging system were captured by the filter that came with the market available mask. A filter flask was used to capture pathogens that broke through the scavenging system supplied filter. The captured pathogens were analyzed and quantified by spread plate analyses for both bacteria and viruses. The filter equipped with the market available scavenging system did not consistently prevent all pathogens from breaking through the filter (p ≥ .05).The HEPA filters in the scavenging mask followed a general trend showing a higher percentage of the smaller viruses passed through the HEPA filter compared to the larger viruses. However, overall the market available scavenging system proved to reduce the exposure to pathogens by 93.2% when exposed to the smallest viruses used (27nm) and as much as 99.9998% for the largest bacteria used (3 μm). Based on this laboratory research, it appears the market available scavenging system may help protect healthcare workers working in the PACU and ICU against airborne pathogen exposure. Further research in clinical trials will help validate these laboratory results

Quantifying nonisothermal subsurface soil water evaporation

Accurate quantification of energy and mass transfer during soil water evaporation is critical for improving understanding of the hydrologic cycle and for many environmental, agricultural, and engineering applications. Drying of soil under radiation boundary conditions results in formation of a dry surface layer (DSL), which is accompanied by a shift in the position of the latent heat sink from the surface to the subsurface. Detailed investigation of evaporative dynamics within this active near-surface zone has mostly been limited to modeling, with few measurements available to test models. Soil column studies were conducted to quantify nonisothermal subsurface evaporation profiles using a sensible heat balance (SHB) approach. Eleven-needle heat pulse probes were used to measure soil temperature and thermal property distributions at the millimeter scale in the near-surface soil. Depth-integrated SHB evaporation rates were compared with mass balance evaporation estimates under controlled laboratory conditions. The results show that the SHB method effectively measured total subsurface evaporation rates with only 0.01–0.03 mm h−1difference from mass balance estimates. The SHB approach also quantified millimeter-scale nonisothermal subsurface evaporation profiles over a drying event, which has not been previously possible. Thickness of the DSL was also examined using measured soil thermal conductivity distributions near the drying surface. Estimates of the DSL thickness were consistent with observed evaporation profile distributions from SHB. Estimated thickness of the DSL was further used to compute diffusive vapor flux. The diffusive vapor flux also closely matched both mass balance evaporation rates and subsurface evaporation rates estimated from SHB

SPICE, A Dataset of Drug-like Molecules and Peptides for Training Machine Learning Potentials

Machine learning potentials are an important tool for molecular simulation, but their development is held back by a shortage of high quality datasets to train them on. We describe the SPICE dataset, a new quantum chemistry dataset for training potentials relevant to simulating drug-like small molecules interacting with proteins. It contains over 1.1 million conformations for a diverse set of small molecules, dimers, dipeptides, and solvated amino acids. It includes 15 elements, charged and uncharged molecules, and a wide range of covalent and non-covalent interactions. It provides both forces and energies calculated at the {\omega}B97M-D3(BJ)/def2-TZVPPD level of theory, along with other useful quantities such as multipole moments and bond orders. We train a set of machine learning potentials on it and demonstrate that they can achieve chemical accuracy across a broad region of chemical space. It can serve as a valuable resource for the creation of transferable, ready to use potential functions for use in molecular simulations.Comment: 19 pages, 6 figure

The Astropy Problem

The Astropy Project (http://astropy.org) is, in its own words, "a community effort to develop a single core package for Astronomy in Python and foster interoperability between Python astronomy packages." For five years this project has been managed, written, and operated as a grassroots, self-organized, almost entirely volunteer effort while the software is used by the majority of the astronomical community. Despite this, the project has always been and remains to this day effectively unfunded. Further, contributors receive little or no formal recognition for creating and supporting what is now critical software. This paper explores the problem in detail, outlines possible solutions to correct this, and presents a few suggestions on how to address the sustainability of general purpose astronomical software

Diasporic Security and Jewish Identity

This paper explores the relationship between identity and security through an investigation into Jewish diasporic identity. The paper argues that the convention of treating identity as an objective referent of security is problematic, as the Jewish diaspora experience demonstrates. The paper presents a new way of conceptualizing identity and security by introducing the concept of diasporic security. Diasporic security reflects the geographical experience of being a member of a trans-state community, of having a fluid identity that is shaped by sometimes contradictory discourses emanating from a community that resides both at home and abroad. In introducing the concept of diasporic security, the paper makes use of literature in Diaspora Studies, Security Studies, recent works in contemporary political theory and sociology, and Woody Allen's film, Deconstructing Harry (1997)

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention